MA03.10 The Interim Analysis of Can-Prevent-Lung Trial: Canakinumab for The Prevention of Lung Cancer
J. Zhang(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Mara B. Antonoff(The University of Texas MD Anderson Cancer Center), M. Godoy(The University of Texas MD Anderson Cancer Center), Marcelo V. Negrão(The University of Texas MD Anderson Cancer Center), G. Walsh(The University of Texas MD Anderson Cancer Center), Morteza Salehjahromi(The University of Texas MD Anderson Cancer Center), Shiaw‐Yih Lin(The University of Texas MD Anderson Cancer Center), Sahar Saeedi Moghaddam(Kiel Institute for the World Economy), Ara A. Vaporciyan(The University of Texas MD Anderson Cancer Center), G.B. Blumenschein(The University of Texas MD Anderson Cancer Center), Reza J. Mehran(The University of Texas MD Anderson Cancer Center), Carl M. Gay(The University of Texas MD Anderson Cancer Center), Boris Sepesi(HealthONE), Lauren A. Byers(The University of Texas MD Anderson Cancer Center), David C. Rice(The University of Texas MD Anderson Cancer Center), Ravi Rajaram(The University of Texas MD Anderson Cancer Center), W. Hofstetter(The University of Texas MD Anderson Cancer Center), J. Wu(The University of Texas MD Anderson Cancer Center), Charles Lu(The University of Texas MD Anderson Cancer Center), Edwin J. Ostrin(The University of Texas MD Anderson Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center)
Cited by 5
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k